News that matters for stocks after hours for June 19th: OMED, NRX, DOM, MEAS, TEL, RHT, JBL, QGEN, REXX, PETX

OncoMed Pharma provides update on FDZ8-Fc (OMP-54F28) Phase 1 clinical trials; Partial clinical hold formally placed on trials (OMED) 

NephroGenex initiates pivotal Phase 3 study with novel treatment to slow progression of diabetic kidney disease (NRX)

 Dominion Resrcs states that its policy is not to comment on unusual market activity (DOM) 

Red Hat beats by $0.01, beats on revs and Billings (RHT) 

Measurement Specialties to be acquired by TE Connectivity (TEL) for $86 cash per share or a total transaction value of ~ $1.7 bln, including assumption of net debt (shares halted) (MEAS)

Jabil Circuit beats by $0.02, beats on revs; guides Q4 EPS in-line, revs in-line; reaffirms FY15 EPS guidance (JBL) 

Qiagen receives FDA approval of artus CMV RGQ MDx kit to monitor Cytomegalovirus (CMV.V) viral load in organ transplant patients (QGEN) 

Rex Energy initiated with an Outperform at Imperial Capital Target $25. REXX

Aratana Therapeutics doses first patient in study of AT-005 PETX

Symbol	Last Sale	Change	% Change	Share Volume	Market
OMED	$25.95	0.87	▲ 3.47%	226,379	NASDAQ-GS
NRX	$6.17	0.24	▲ 4.05%	7,788	NASDAQ-CM
DOM	$6.81	2.96	▼ 30.3%	1,645,328	NYSE
MEAS	$78	0.25	▲ 0.32%	122,887	NASDAQ-GS
TEL	$61.94	0.16	▲ 0.26%	853,631	NYSE
RHT	$53.1	0.67	▲ 1.28%	3,296,808	NYSE
JBL	$20.1	0.13	▲ 0.65%	3,319,519	NYSE
QGEN	$24.2	0.68	▲ 2.89%	1,357,849	NASDAQ-GS
REXX	$18.56	0.16	▲ 0.87%	879,149	NASDAQ-GS
PETX	$15.72	0.84	▲ 5.65%	300,796	NASDAQ-GM